Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. and Thun, M.J: Cancer statistics CA Cancer J Clin 55:10–30, 2005.
Nelson, BH: Regulatory T-cells and Tolerance. J. Immunol. 172:3983–3988, 2004.
Gaffen, S.L.: Signaling domains of the interleukin 2 receptor. Cytokine 14:63–77, 2001.
He, Y.W. and Malek T.R: The structure and function of γc-dependent cytokines and receptors: regulation of T lymphocytes development and homeostasis. Crit. Rev. Immunol 18, 503–524, 1998.
Parrish-Novak, J., Foster, D.C., Holly, R.D. and Clegg, C.H: Interleukin-21 and the IL-21 receptor; novel effectors of NK and T cell responses. J. Leukoc. Biol 72, 856–863, 2002.
Rosenberg, S., Lotze, M., Muul, L., Leitman, S., Chang, A., Ettinghausen, S., Matory, Y., Skibber, J., Shiloni, E., Vetto, J., et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313:1485–1492, 1985.
Lotze, M., Chang, A., Seipp, C., Simpson, C., Vetto, J., and Rosenberg, S: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. JAMA 256:3117–3124, 1986.
Sadlack, B. et al: Ulcerative colitis-like disease in mice with a disrupted interleukin-gene. Cell 75, 253–261 1993.
Sadlack, B. et al: Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol 25, 3053–3059,1995.
Sadlack, B., Kuhn, R., Schorle, H., Muller, W. & Horak, I: Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur. J. Immunol. 24, 281–284, 1994.
Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L: CD4 regulatory T cells prevent lethal autoimmunity in IL-2R-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167–178, 2002.
Malek, T. R., Porter, B. O., Codias, E. K., Scibelli, P. & Yu, A: Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J. Immunol 164, 2905–2914, 2004.
Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nature Rev Immunol 4:665–674, 2004.
Depper, J. M., Leonard, W. J., Robb, R. J., Waldmann, T. A. & Greene, W. C: Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J. Immunol 131, 690–696, 1983.
Gillis, S., Gillis, A. E. & Henney, C. S: Monoclonal antibody directed against interleukin 2 : Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells. J. Exp. Med. 154, 983–988, 1981.
Van Parijs, L. et al: Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158, 3738–3745,1997.
Kundig, T. M. et al. Immune responses in interleukin-2-deficient mice. Science 262, 1059–1061, 1993.
D’Souza, W. N. & Lefrancois, L: IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol 171, 5727–5735, 2003.
Leung, D. T., Morefield, S. & Willerford, D. M: Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo. J. Immunol 164, 3527–3534, 2000.
Lotze, M., Grimm, E., Mazumder, A., Strausser, J., and Rosenberg, S: In vitro growth of cytotoxic human lymphocytes. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res 41:4420, 1981.
Mazumder, A., and Rosenberg, S: Successful immunotherapy of natural killer-resistant established pulmonary metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159:495, 1984.
Rosenberg, S., Mule, J., Spiess, P., Reichert, C., and Schwarz, S: Regression of Established Pulmonary Metastases and Subcutaneous Tumor Mediated by the Systemic Administration of High-Dose Recombinant Interleukin 2. J Exp Med 161:1169–1188, 1985.
Rosenberg, S., Lotze, M., Muul, L., Leitman, S., Chang, A., Ettinghausen, S., Matory, Y., Skibber, J., Shiloni, E., Vetto, J., et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313:1485–1492.
Lotze, M., Chang, A., Seipp, C., Simpson, C., Vetto, J., and Rosenberg, S. 1986. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. JAMA 256:117–3124, 1985.
Rosenberg, S., Lotze, M., Muul, L., Chang, A., Avis, F., Leitman, S., Linehan, W., Robertson, C., Lee, R., Rubin, J., et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 316:889–897, 1987.
Atkins, M., Lotze, M., Dutcher, J., Fisher, R., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116, 1999.
Rosenberg, S., Yang, J., White, D., and Steinberg, S: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 228:307–319, 1998.
Sparano, J., Fisher, R., Sunderland, M., Margolin, K., Ernest, M., Sznol, M., Atkins, M., Dutcher, J., Micetich, K., Weiss, G., et al: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha-2a in patients with advanced melanoma. J Clin Oncol 11:1969–1977, 1993.
Eton, O., Legha, S., Bedikian, A., Lee, J., Buzaid, A., Hodges, C., Ring, S., Papadopoulos, N., Plager, C., East, M., et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045–2052, 2002.
Keilholz, U., Goey, S., Punt, C., Proebstle, T., Salzmann, R., Scheibenbogen, C., Schadendorf, D., Liendard, D., Enk, A., Dummer, R., et al: Interferon-alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for the Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579–2588, 1997.
Rosenberg, S., Yang, J., Schwartzentruber, D., Hwu, P., Marincola, F., Topalian, S., Seipp, C., Einhorn, J., White, D., and Steinberg, S: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone, or in combination with interleukin-2 and interferon-alfa-2b. J Clin Oncol 17:968–975, 1999.
Keilholz, U., Punt, C., Gore, M., Suciu, S., Kruit, W., Patel, P., Lienard, D., Thomas, J., Lehmann, F., and Eggermont, A: Dacarbazine, cisplatin and IFN-a2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. In ASCO. Chicago. 708 (abst 2848), 2003.
Atkins, M., Lee, S., Flaherty, L., Sosman, J., Sondak, V., and Kirkwood, J: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. In ASCO. Chicago. 708 (abstr 2847), 2003.
Fisher, R.I., Coltman, C.A., Jr., Doroshow, J.H., Rayner, A.A., Hawkins, M.J., Mier, J.W., Wiernik, P., McMannis, J.D., Weiss, G.R., Margolin, K.A., et al: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 108:518–523, 1988.
Fyfe, G., Fisher, R.I., Rosenberg, S.A., Sznol, M., Parkinson, D.R., and Louie, A.C: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696, 1995.
Fisher, R.I., Rosenberg, S.A., and Fyfe, G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 Suppl 1:S55–57, 2000.
Bukowski, R.M: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198–1220, 1997.
Yang, JC, Sherry, RM, Steinberg, SM, Topalian, SL, Schwartzentruber, DJ, Hwu, P, Seipp, CA, Rogers-Freezer, L, Morton, KE, White, DE, Liewehr, DJ, Merino, MJ, Rosenberg, SA: Randomized Study of High-Dose and Low Dose Interleukin-2 in patients with Metastatic Renal Cancer. J Clin Oncol Aug 15;21 (16):3127–32, 2003.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Eng J Med 345(23): 1655–59, 2001.
Pantuck AJ, Belldegrun AS, Figlin RA: Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 345(23) 1711–1712, 2001.
Marincola, F., Venzon, D., White, D., Rubin, J., Lotze, M., Simonis, T., Balkissoon, J., Rosenberg, S., and Parkinson, D: HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 52:6561–6566, 1992.
Rubin, J., Elwood, L., Rosenberg, S., and Lotze, M: Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49:7086–7092, 1986.
Horikoshi, T., Ito, S., Wakamatsu, K., Onodera, H., and Eguchi, H: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73:629–636, 1994.
Phan, G., Attia, P., Steinberg, S., White, D., and Rosenberg, S: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 19:3477–3482, 2001.
Jonasch E, George D, Atkins MB: Renal neoplasia. In: Brenner B, ed. Brenner & Rector’s The Kidney, 7th ed. Philadelphia: Saunders; 1895–1923, 2004.
Royal RE, Steinberg SM, Krouse RS, et al: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 2:91, 1996.
Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunol 28: 488–95, 2005.
Said J: Biomarker discover in urogenital cancer. Biomarkers Nov;10 Suppl 1:S83–6, 2005.
Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for pronosis and therapy. Clin Cancer Res 9:802–811, 2003.
Mukouyama H, Janzen NK, Hernandez JM, et al: Generation of kidney cancer-specific antitumor immune responses using peripheral blood moncytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 10:1421–1429, 2004.
Schwartzentruber, D: Guidelines for the Safe Administration of High-Dose Interleukin-2. J Immunother 24:287–293, 2001.
Guirguis, LM, Yang, JC, White, DE, Steinberg SM, Liewehr, DJ, Rosenberg ,SA, Schwartzentruber, DJ: Safety and efficacy of high-dose Interleukin-2 therapy in patients with brain metastases. J Immunother Jan-Feb; 25(1):82–7, 2002.
Mier, J., Vachino, G., Klempner, M., Aaronson, F., Noring, R., Smith, S., Brandon, E., Laird, W., and Atkins, M: Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76:1933–1940, 1990.
Du Bois, J., Trehu, E., Mier, J., Shapiro, L., Epstein, M., Klempner, M., Dinarello, C., Kappler, K., Ronayne, L., Rand, W., et al: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 15:1052–1062,1997.
Kilbourn, R., Fonseca, G., Trissel, L., and Griffith, O: Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Cancer J Sci Am 6:S21–30, 2000.
Samlowski, W., Petersen, R., Cuzzocrea, S., Macarthur, H., Burton, D., McGregor, J., and Salvemimi, D: A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med 9:750–755, 2003.
Dillman, R., O’Connor, A., Simpson, L., Barth, N., VanderMolen, L., and Vanderplas, P: Does Continuous-Infusion Interleukin-2 Increase Survival in Metastatic Melanoma? Am J Clin Oncol 26:141–145, 2003.
Thompson, J., Lee, D., Lindgren, C., Benz, L., Collins, C., Levitt, D., and Fefer, A: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6:669–678, 1988.
Liu, K., and Rosenberg, S: Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother 26:190–201, 2003.
Radny, P., Caroli, U., Bauer, J., Paul, T., Schlegel, C., Eigentler, T., Weide, B., Schwarz, M., and Garbe, C: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89:1620–1626, 2003.
Mahnke, K., Qian, Y., Knop, J., and Enk, A: Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101:4862–4869, 2003.
Shimizu, J., Yamazaki, S., and Sakaguchi, S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 163:5211–5218, 1999.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
Petrulio, C.A., DeRaffele, G., Kaufman, H.L. (2007). High Dose Interleukin-2 Therapy. In: Kaufman, H.L., Wolchok, J.D. (eds) General Principles of Tumor Immunotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6087-8_19
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6087-8_19
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6086-1
Online ISBN: 978-1-4020-6087-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)